Dr  Tracy Dudding

Dr Tracy Dudding

Conjoint Professor

School of Medicine and Public Health (Medical Genetics)

Career Summary

Biography

Professor Tracy Dudding-Byth AM works as a Consultant Clinical Geneticist within the NSW Genetics of Learning Disability (GOLD) Service, Hunter Genetics, NSW Australia.  She is a clinician-researcher in the field of neurofibromatosis type 1, rare genetic diseases, obtaining her PhD in 2012. She was a founding co-director of Rare Voices Australia, a national advocacy organisation uniting the estimated 1.5 million Australians living with a rare disease. 

Research interests: My research interests include identifying the genetic modifiers affecting the severity of neurofibromatosis type 1 (NF1) to develop a targeted treatment for individuals with this condition; and the use of 2D facial recognition technology to improve the diagnostic rate for children with syndromic intellectual disability. The FaceMatch computer vision platform (facematch.org.au) is the first and only combined clinician and computer vision initiative to integrate facial matching over the age spectrum with human phenome ontology terms and genomic variant data. Dr Dudding-Byth recieved the 2021 Research Australia Health and Medical Research Data Innovation award for developing the FaceMatch project. 

Neurofibromatosis Research:

Neurofibromatosis type 1 Cutaneous Neurofibroma Consortium is a research project funded by a $1.6M grant from the Medical Research Future Fund which I am leading. It aims to increase the understanding of how genetics influences the number of skin neurofibromas a person with NF1 may develop and how to treat neurofibromas in the future. 

The study is open to adults with clinical or genetic diagnosis of NF1. Participants can register at NF1 project 

Neurofibromatosis type 1 (NF1) is one the most common neurogenetic conditions with a prevalence of 1 in 2500. Children and adults with this condition have an increased lifetime risk of benign and malignant tumours affecting the skin and nervous system. There are no current treatment for cutaneous neurofibromas which have an incredibly high physical and psychological burden for affected individuals. I believe that studying this condition will provide insights into the pathogenesis of more common cancers. 

Publications: Research output includes 33 publications (11 first or senior author) and 1 PhD Thesis. This includes 1 Nature and 2 Nature Genetics publications as part of the KConFab consortium. Citation index:14

Contribution to field of research: As a clinical researcher, Dr Dudding-Byth has phenotypically and molecularly characterised a novel form of intellectual disability (Omim 117360) (Dudding et al., Neurology 2004; Huang et al Orphanet J Rare dis. 2012) and a novel form of oesophageal achalasia (Dudding et al., 2010 Clin Genet). She has extended the phenotypic characterisation of four genetic causes of intellectual disability. Her work exploring the relationship between inherited thrombophilia and adverse pregnancy outcome (Dudding et al., Thrombosis and Haemostasis 2004; Dudding et al J Thrombosis and Haemostasis) is referenced within UptoDate: Inherited thrombophilia and pregnancy; Gene reviews- inherited thrombophilia; and in the British Journal of Haematology: clinical guidelines for the testing for inherited thrombophilia. 

International collaboration:The GOLD service has well established collaborations with the Max Planck institute, Germany and the Wellcome Trust Sanger Institute, England. Care4Rare collaboration led to the identification of the gene for SCA29. Dr Dudding-Byth is leading an innovative project with Professor Brian Lovell from The University of Queensland evaluating the use of 2D facial recognition technology for matching the gestalt of individuals with known and unknown syndromic forms of intellectual disability [Oral presentation HGSA conference August 2015]. 

Research Support: Chief Investigator on University of Newcastle Grow-Up-Well Priority Research Centre Grant 2015. HNEhealth 2015 Innovation Scholarship: " The FaceMatch Project: Matching the faces of individuals with undiagnosed syndromic intellectual disability".

Community engagement: Co-founding director of Rare Voices Australia.  Dr Dudding-Byth sits on the Medical Advisory Committee of the Steve Waugh Foundation, a charity for children with rare diseases. 

2013: Invited speaker: RCPA Pathology:Australasian Division 37th Annual Scientific Meeting. Orphan Diseases: Challenges, Costs and Opportunities
2015: RACGP invited manuscript submission: A Powerful team: the family physician advocating for patients with a rare disease.

Supervision and mentoring: Dr Dudding-Byth is supervising 3 higher degree students in the field of rare disease research. She supervises medical students during their year 5 Special Study Option to write and publish a first author medical case report. Awarded HCRF 2015 Research Mentor of the year. 


Qualifications

  • Doctor of Philosophy, University of Newcastle
  • Bachelor of Medicine, University of Newcastle

Keywords

  • 2D facial recognition technology in dysmorphology
  • Neurofibromatosis type 1
  • clinical genetics
  • intellectual disability
  • medical genetics
  • rare disease patient advocacy
  • rare genetic diseases

Professional Experience

Membership

Dates Title Organisation / Department
1/1/2012 -  Founding Director Rare Voices Australia
Australia
1/1/2012 -  Medical Advisory Committee Steve Waugh Foundation - Australia Inc.

Professional appointment

Dates Title Organisation / Department
1/2/2017 - 1/2/2020 HNEHealth 2016 Clinical Research Fellow

Health Research and Translation Centre, Partnerships Innovation and Research

2015 Clinical Research Fellowship to support the "FACEMATCH Searching for a diagnosis" Project

Hunter New England Area Health Service
Australia
1/1/2013 -  Senior Staff Specialist Clinical Genetics Hunter Genetics, Hunter Area Health Service
Australia
1/1/2013 -  Senior Staff Specialist NSW GOLD Service Hunter Genetics, Hunter Area Health Service
Australia

Awards

Research Award

Year Award
1997 Hunter Area Health Service Career Development Fund
Hunter Area Health Service

Scholarship

Year Award
1997 World Health Organisation (WHO) Travelling Scholarship
World Health Organization
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (79 outputs)

Year Citation Altmetrics Link
2024 Pisan E, De Luca C, Brancati F, Sanchez Russo R, Li D, Bhoj E, et al., 'The spectrum of heart defects in the TRAF7-related multiple congenital anomalies-intellectual disability syndrome.', Proc Natl Acad Sci U S A, 121 e2317601121 (2024)
DOI 10.1073/pnas.2317601121
2023 Selvanathan A, Forwood C, Russell J, Batten K, Thompson S, Palmer EE, et al., 'Rapid whole-genome sequencing leading to specific treatment for two infants with haemophagocytic lymphohistiocytosis due to Wolman disease', PEDIATRIC BLOOD & CANCER, 70 (2023)
DOI 10.1002/pbc.30394
Citations Scopus - 1
2023 Rossi A, Blok LS, Neuser S, Klöckner C, Platzer K, Faivre LO, et al., 'POU3F3-related disorder: Defining the phenotype and expanding the molecular spectrum', Clinical Genetics, 104 186-197 (2023) [C1]

POU3F3 variants cause developmental delay, behavioral problems, hypotonia and dysmorphic features. We investigated the phenotypic and genetic landscape, and genotype¿phenotype cor... [more]

POU3F3 variants cause developmental delay, behavioral problems, hypotonia and dysmorphic features. We investigated the phenotypic and genetic landscape, and genotype¿phenotype correlations in individuals with POU3F3-related disorders. We recruited unpublished individuals with POU3F3 variants through international collaborations and obtained updated clinical data on previously published individuals. Trio exome sequencing or single exome sequencing followed by segregation analysis were performed in the novel cohort. Functional effects of missense variants were investigated with 3D protein modeling. We included 28 individuals (5 previously published) from 26 families carrying POU3F3 variants; 23 de novo and one inherited from an affected parent. Median age at study inclusion was 7.4 years. All had developmental delay mainly affecting speech, behavioral difficulties, psychiatric comorbidities and dysmorphisms. Additional features included gastrointestinal comorbidities, hearing loss, ophthalmological anomalies, epilepsy, sleep disturbances and joint hypermobility. Autism, hearing and eye comorbidities, dysmorphisms were more common in individuals with truncating variants, whereas epilepsy was only associated with missense variants. In silico structural modeling predicted that all (likely) pathogenic variants destabilize the DNA-binding region of POU3F3. Our study refined the phenotypic and genetic landscape of POU3F3-related disorders, it reports the functional properties of the identified pathogenic variants, and delineates some genotype¿phenotype correlations.

DOI 10.1111/cge.14353
Citations Scopus - 1
2023 Leffler M, Christie L, Hackett A, Bennetts B, Goel H, Amor DJ, et al., 'Further delineation of dosage-sensitive K/L mediated Xq28 duplication syndrome includes incomplete penetrance.', Clin Genet, 103 681-687 (2023) [C1]
DOI 10.1111/cge.14303
Co-authors A Hackett
2023 Brazane M, Dimitrova DG, Pigeon J, Paolantoni C, Ye T, Marchand V, et al., 'The ribose methylation enzyme FTSJ1 has a conserved role in neuron morphology and learning performance.', Life Sci Alliance, 6 (2023) [C1]
DOI 10.26508/lsa.202201877
Citations Scopus - 2
2023 Forwood C, Ashton K, Zhu Y, Zhang F, Dias KR, Standen K, et al., 'Integration of EpiSign, facial phenotyping, and likelihood ratio interpretation of clinical abnormalities in the re-classification of an ARID1B missense variant', American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 193 (2023) [C1]

Heterozygous ARID1B variants result in Coffin¿Siris syndrome. Features may include hypoplastic nails, slow growth, characteristic facial features, hypotonia, hypertrichosis, and s... [more]

Heterozygous ARID1B variants result in Coffin¿Siris syndrome. Features may include hypoplastic nails, slow growth, characteristic facial features, hypotonia, hypertrichosis, and sparse scalp hair. Most reported cases are due to ARID1B loss of function variants. We report a boy with developmental delay, feeding difficulties, aspiration, recurrent respiratory infections, slow growth, and hypotonia without a clinical diagnosis, where a previously unreported ARID1B missense variant was classified as a variant of uncertain significance. The pathogenicity of this variant was refined through combined methodologies including genome-wide methylation signature analysis (EpiSign), Machine Learning (ML) facial phenotyping, and LIRICAL. Trio exome sequencing and EpiSign were performed. ML facial phenotyping compared facial images using FaceMatch and GestaltMatcher to syndrome-specific libraries to prioritize the trio exome bioinformatic pipeline gene list output. Phenotype-driven variant prioritization was performed with LIRICAL. A de novo heterozygous missense variant, ARID1B p.(Tyr1268His), was reported as a variant of uncertain significance. The ACMG classification was refined to likely pathogenic by a supportive methylation signature, ML facial phenotyping, and prioritization through LIRICAL. The ARID1B genotype¿phenotype has been expanded through an extended analysis of missense variation through genome-wide methylation signatures, ML facial phenotyping, and likelihood-ratio gene prioritization.

DOI 10.1002/ajmg.c.32056
Citations Scopus - 2
Co-authors Carlos Riveros
2023 Palmer EE, Pusch M, Picollo A, Forwood C, Nguyen MH, Suckow V, et al., 'Functional and clinical studies reveal pathophysiological complexity of CLCN4-related neurodevelopmental condition', Molecular Psychiatry, 28 668-697 (2023) [C1]

Missense and truncating variants in the X-chromosome-linked CLCN4 gene, resulting in reduced or complete loss-of-function (LOF) of the encoded chloride/proton exchanger ClC-4, wer... [more]

Missense and truncating variants in the X-chromosome-linked CLCN4 gene, resulting in reduced or complete loss-of-function (LOF) of the encoded chloride/proton exchanger ClC-4, were recently demonstrated to cause a neurocognitive phenotype in both males and females. Through international clinical matchmaking and interrogation of public variant databases we assembled a database of 90 rare CLCN4 missense variants in 90 families: 41 unique and 18 recurrent variants in 49 families. For 43 families, including 22 males and 33 females, we collated detailed clinical and segregation data. To confirm causality of variants and to obtain insight into disease mechanisms, we investigated the effect on electrophysiological properties of 59 of the variants in Xenopus oocytes using extended voltage and pH ranges. Detailed analyses revealed new pathophysiological mechanisms: 25% (15/59) of variants demonstrated LOF, characterized by a ¿shift¿ of the voltage-dependent activation to more positive voltages, and nine variants resulted in a toxic gain-of-function, associated with a disrupted gate allowing inward transport at negative voltages. Functional results were not always in line with in silico pathogenicity scores, highlighting the complexity of pathogenicity assessment for accurate genetic counselling. The complex neurocognitive and psychiatric manifestations of this condition, and hitherto under-recognized impacts on growth, gastrointestinal function, and motor control are discussed. Including published cases, we summarize features in 122 individuals from 67 families with CLCN4-related neurodevelopmental condition and suggest future research directions with the aim of improving the integrated care for individuals with this diagnosis.

DOI 10.1038/s41380-022-01852-9
Citations Scopus - 11Web of Science - 4
2022 Bournazos AM, Riley LG, Bommireddipalli S, Ades L, Akesson LS, Al-Shinnag M, et al., 'Standardized practices for RNA diagnostics using clinically accessible specimens reclassifies 75% of putative splicing variants', Genetics in Medicine, 24 130-145 (2022) [C1]

Purpose: Genetic variants causing aberrant premessenger RNA splicing are increasingly being recognized as causal variants in genetic disorders. In this study, we devise standardiz... [more]

Purpose: Genetic variants causing aberrant premessenger RNA splicing are increasingly being recognized as causal variants in genetic disorders. In this study, we devise standardized practices for polymerase chain reaction (PCR)-based RNA diagnostics using clinically accessible specimens (blood, fibroblasts, urothelia, biopsy). Methods: A total of 74 families with diverse monogenic conditions (31% prenatal-congenital onset, 47% early childhood, and 22% teenage-adult onset) were triaged into PCR-based RNA testing, with comparative RNA sequencing for 19 cases. Results: Informative RNA assay data were obtained for 96% of cases, enabling variant reclassification for 75% variants that can be used for genetic counseling (71%), to inform clinical care (32%) and prenatal counseling (41%). Variant-associated mis-splicing was highly reproducible for 28 cases with samples from =2 affected individuals or heterozygotes and 10 cases with =2 biospecimens. PCR amplicons encompassing another segregated heterozygous variant was vital for clinical interpretation of 22 of 79 variants to phase RNA splicing events and discern complete from partial mis-splicing. Conclusion: RNA diagnostics enabled provision of a genetic diagnosis for 64% of recruited cases. PCR-based RNA diagnostics has capacity to analyze 81.3% of clinically significant genes, with long amplicons providing an advantage over RNA sequencing to phase RNA splicing events. The Australasian Consortium for RNA Diagnostics (SpliceACORD) provide clinically-endorsed, standardized protocols and recommendations for interpreting RNA assay data.

DOI 10.1016/j.gim.2021.09.001
Citations Scopus - 37Web of Science - 16
Co-authors Rodney Scott, Saxon White
2022 Huang L, Warman-Chardon J, Carter MT, Friend KL, Dudding TE, Schwartzentruber J, et al., 'Missense mutations in ITPR1 cause autosomal dominant congenital nonprogressive spinocerebellar ataxia (vol 7, 67, 2012)', ORPHANET JOURNAL OF RARE DISEASES, 17 (2022)
DOI 10.1186/s13023-022-02297-7
Co-authors Peter Schofield
2022 Baker EK, Merton CF, Tan W-H, Dudding-Byth T, Godler DE, Sadhwani A, 'Methylation analysis and developmental profile of two individuals with Angelman syndrome due to mosaic imprinting defects', EUROPEAN JOURNAL OF MEDICAL GENETICS, 65 (2022)
DOI 10.1016/j.ejmg.2022.104456
Citations Scopus - 2
2022 Shoubridge C, Dudding-Byth T, Pasquier L, Goel H, Yap P, McConnell V, 'IQSEC2-related encephalopathy in males due to missense variants in the pleckstrin homology domain', Clinical Genetics, 102 72-77 (2022) [C1]

Pathogenic variants in IQ motif and SEC7 domain containing protein 2 (IQSEC2) gene cause a variety of neurodevelopmental disorders, with intellectual disability as a uniform featu... [more]

Pathogenic variants in IQ motif and SEC7 domain containing protein 2 (IQSEC2) gene cause a variety of neurodevelopmental disorders, with intellectual disability as a uniform feature. We report five cases, each with a novel missense variant in the pleckstrin homology (PH) domain of the IQSEC2 protein. Male patients all present with moderate to profound intellectual disability, significant delays or absent language and speech and variable seizures. We describe the phenotypic spectrum associated with missense variants in PH domain of IQSEC2, further delineating the genotype¿phenotype correlation for this X-linked gene.

DOI 10.1111/cge.14136
Citations Scopus - 2Web of Science - 2
2022 Choufani S, McNiven V, Cytrynbaum C, Jangjoo M, Adam MP, Bjornsson HT, et al., 'An HNRNPK-specific DNA methylation signature makes sense of missense variants and expands the phenotypic spectrum of Au-Kline syndrome', AMERICAN JOURNAL OF HUMAN GENETICS, 109 1867-1884 (2022) [C1]
DOI 10.1016/j.ajhg.2022.08.014
Citations Scopus - 10Web of Science - 5
2022 Cornell P, Armstrong T, Fyfe R, Mallise CA, Dudding-Byth T, Campbell LE, 'Experiences of non-invasive prenatal screening: A survey study', Australian and New Zealand Journal of Obstetrics and Gynaecology, 62 241-249 (2022) [C1]

Background:: In Australia, using non-invasive prenatal testing (NIPT) to screen for fetal abnormalities is becoming more commonplace. However, there is a lack of standardised proc... [more]

Background:: In Australia, using non-invasive prenatal testing (NIPT) to screen for fetal abnormalities is becoming more commonplace. However, there is a lack of standardised procedures surrounding pre-test counselling. This holds the potential for variability in pregnant people¿s experiences when undergoing NIPT, which subsequently may impact their ability to make informed decisions surrounding NIPT results. Aim:: This study sought to characterise the experiences of Australian women undergoing NIPT, including perceptions of informed choice, counselling experiences and decision to undergo NIPT. Materials and Methods:: Australian women who had been recently pregnant (n¿=¿94) completed an online survey which assessed: their knowledge of and attitude toward NIPT; satisfaction with counselling; satisfaction with their decision; and decisional conflict to undergo NIPT. The survey also allowed participants to provide qualitative information about their counselling experience and reasons for undergoing NIPT. Results:: Overall, participants had good knowledge of and positive attitudes toward NIPT, experienced low decisional conflict and were overall satisfied with their counselling experience and decision to undergo NIPT. However, some participants expressed dissatisfaction with the lack of information provided, and biased language, by counselling providers. The desire to be informed was the most frequent reason for undergoing NIPT. Conclusion:: The provision of accurate and objective information in pre-test counselling is important to reduce decisional conflict and improve satisfaction with the decision to undergo NIPT. It is recommended counselling providers present pregnant people with neutral, objective, and accurate information at the time of pre-test counselling.

DOI 10.1111/ajo.13436
Citations Scopus - 8Web of Science - 3
Co-authors Carly Mallise, Linda E Campbell
2021 Bruinsma FJ, Jordan S, Bassett JK, Severi G, MacInnis RJ, Walsh J, et al., 'Analgesic use and the risk of renal cell carcinoma-Findings from the Consortium for the Investigation of Renal Malignancies (CONFIRM) study', CANCER EPIDEMIOLOGY, 75 (2021) [C1]
DOI 10.1016/j.canep.2021.102036
Citations Scopus - 1Web of Science - 1
2021 Field MJ, Kumar R, Hackett A, Kayumi S, Shoubridge CA, Ewans LJ, et al., 'Different types of disease-causing noncoding variants revealed by genomic and gene expression analyses in families with X-linked intellectual disability', Human Mutation, 42 835-847 (2021) [C1]

The pioneering discovery research of X-linked intellectual disability (XLID) genes has benefitted thousands of individuals worldwide; however, approximately 30% of XLID families s... [more]

The pioneering discovery research of X-linked intellectual disability (XLID) genes has benefitted thousands of individuals worldwide; however, approximately 30% of XLID families still remain unresolved. We postulated that noncoding variants that affect gene regulation or splicing may account for the lack of a genetic diagnosis in some cases. Detecting pathogenic, gene-regulatory variants with the same sensitivity and specificity as structural and coding variants is a major challenge for Mendelian disorders. Here, we describe three pedigrees with suggestive XLID where distinctive phenotypes associated with known genes guided the identification of three different noncoding variants. We used comprehensive structural, single-nucleotide, and repeat expansion analyses of genome sequencing. RNA-Seq from patient-derived cell lines, reverse-transcription polymerase chain reactions, Western blots, and reporter gene assays were used to confirm the functional effect of three fundamentally different classes of pathogenic noncoding variants: a retrotransposon insertion, a novel intronic splice donor, and a canonical splice variant of an untranslated exon. In one family, we excluded a rare coding variant in ARX, a known XLID gene, in favor of a regulatory noncoding variant in OFD1 that correlated with the clinical phenotype. Our results underscore the value of genomic research on unresolved XLID families to aid novel, pathogenic noncoding variant discovery.

DOI 10.1002/humu.24207
Co-authors A Hackett
2019 Field M, Dudding-Byth T, Arpone M, Baker EK, Aliaga SM, Rogers C, et al., 'Significantly Elevated FMR1 mRNA and Mosaicism for Methylated Premutation and Full Mutation Alleles in Two Brothers with Autism Features Referred for Fragile X Testing', INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 20 (2019)
DOI 10.3390/ijms20163907
Citations Scopus - 14Web of Science - 9
2019 McCabe MJ, Gauthier MEA, Chan CL, Thompson TJ, De Sousa SMC, Puttick C, et al., 'Development and validation of a targeted gene sequencing panel for application to disparate cancers', Scientific Reports, 9 (2019) [C1]

Next generation sequencing has revolutionised genomic studies of cancer, having facilitated the development of precision oncology treatments based on a tumour¿s molecular profile.... [more]

Next generation sequencing has revolutionised genomic studies of cancer, having facilitated the development of precision oncology treatments based on a tumour¿s molecular profile. We aimed to develop a targeted gene sequencing panel for application to disparate cancer types with particular focus on tumours of the head and neck, plus test for utility in liquid biopsy. The final panel designed through Roche/Nimblegen combined 451 cancer-associated genes (2.01 Mb target region). 136 patient DNA samples were collected for performance and application testing. Panel sensitivity and precision were measured using well-characterised DNA controls (n = 47), and specificity by Sanger sequencing of the Aryl Hydrocarbon Receptor Interacting Protein (AIP) gene in 89 patients. Assessment of liquid biopsy application employed a pool of synthetic circulating tumour DNA (ctDNA). Library preparation and sequencing were conducted on Illumina-based platforms prior to analysis with our accredited (ISO15189) bioinformatics pipeline. We achieved a mean coverage of 395x, with sensitivity and specificity of >99% and precision of >97%. Liquid biopsy revealed detection to 1.25% variant allele frequency. Application to head and neck tumours/cancers resulted in detection of mutations aligned to published databases. In conclusion, we have developed an analytically-validated panel for application to cancers of disparate types with utility in liquid biopsy.

DOI 10.1038/s41598-019-52000-3
Citations Scopus - 15Web of Science - 11
Co-authors Rodney Scott
2019 Li A, Geyer FC, Blecua P, Lee JY, Selenica P, Brown DN, et al., 'Homologous recombination DNA repair defects in PALB2-associated breast cancers (vol 5, 23, 2019)', NPJ BREAST CANCER, 5 (2019)
DOI 10.1038/s41523-019-0140-8
Co-authors Rodney Scott, John Forbes
2019 Nellaker C, Alkuraya FS, Baynam G, Bernier RA, Bernier FPJ, Boulangerw V, et al., 'Enabling Global Clinical Collaborations on Identifiable Patient Data: The Minerva Initiative', FRONTIERS IN GENETICS, 10 (2019)
DOI 10.3389/fgene.2019.00611
Citations Scopus - 11Web of Science - 8
2019 Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, et al., 'Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes', American Journal of Human Genetics, 104 21-34 (2019) [C1]

Stratification of women according to their risk of breast cancer based on polygenic risk scores (PRSs) could improve screening and prevention strategies. Our aim was to develop PR... [more]

Stratification of women according to their risk of breast cancer based on polygenic risk scores (PRSs) could improve screening and prevention strategies. Our aim was to develop PRSs, optimized for prediction of estrogen receptor (ER)-specific disease, from the largest available genome-wide association dataset and to empirically validate the PRSs in prospective studies. The development dataset comprised 94,075 case subjects and 75,017 control subjects of European ancestry from 69 studies, divided into training and validation sets. Samples were genotyped using genome-wide arrays, and single-nucleotide polymorphisms (SNPs) were selected by stepwise regression or lasso penalized regression. The best performing PRSs were validated in an independent test set comprising 11,428 case subjects and 18,323 control subjects from 10 prospective studies and 190,040 women from UK Biobank (3,215 incident breast cancers). For the best PRSs (313 SNPs), the odds ratio for overall disease per 1 standard deviation in ten prospective studies was 1.61 (95%CI: 1.57¿1.65) with area under receiver-operator curve (AUC) = 0.630 (95%CI: 0.628¿0.651). The lifetime risk of overall breast cancer in the top centile of the PRSs was 32.6%. Compared with women in the middle quintile, those in the highest 1% of risk had 4.37- and 2.78-fold risks, and those in the lowest 1% of risk had 0.16- and 0.27-fold risks, of developing ER-positive and ER-negative disease, respectively. Goodness-of-fit tests indicated that this PRS was well calibrated and predicts disease risk accurately in the tails of the distribution. This PRS is a powerful and reliable predictor of breast cancer risk that may improve breast cancer prevention programs.

DOI 10.1016/j.ajhg.2018.11.002
Citations Scopus - 584Web of Science - 408
Co-authors Rodney Scott, John Forbes
2019 Khayat W, Hackett A, Shaw M, Ilie A, Dudding-Byth T, Kalscheuer VM, et al., 'A recurrent missense variant in SLC9A7 causes nonsyndromic X-linked intellectual disability with alteration of Golgi acidification and aberrant glycosylation', Human Molecular Genetics, 28 598-614 (2019) [C1]

We report two unrelated families with multigenerational nonsyndromic intellectual disability (ID) segregating with a recurrent de novo missense variant (c.1543CT:p.Leu515Phe) in t... [more]

We report two unrelated families with multigenerational nonsyndromic intellectual disability (ID) segregating with a recurrent de novo missense variant (c.1543CT:p.Leu515Phe) in the alkali cation/proton exchanger gene SLC9A7 (also commonly referred to as NHE7). SLC9A7 is located on human X chromosome at Xp11.3 and has not yet been associated with a human phenotype. The gene is widely transcribed, but especially abundant in brain, skeletal muscle and various secretory tissues.Within cells, SLC9A7 resides in the Golgi apparatus, with prominent enrichment in the trans-Golgi network (TGN) and post-Golgi vesicles. In transfected Chinese hamster ovary AP-1 cells, the Leu515Phe mutant protein was correctly targeted to the TGN/post-Golgi vesicles, but its N-linked oligosaccharide maturation as well as that of a co-transfected secretory membrane glycoprotein, vesicular stomatitis virus G (VSVG) glycoprotein, was reduced compared to cells co-expressing SLC9A7 wild-type and VSVG. This correlated with alkalinization of the TGN/post-Golgi compartments, suggestive of a gain-of-function. Membrane trafficking of glycosylation-deficient Leu515Phe and co-transfected VSVG to the cell surface, however, was relatively unaffected. Mass spectrometry analysis of patient sera also revealed an abnormal.

DOI 10.1093/hmg/ddy371
Citations Scopus - 22
Co-authors A Hackett
2019 Shoubridge C, Harvey RJ, Dudding-Byth T, 'IQSEC2 mutation update and review of the female-specific phenotype spectrum including intellectual disability and epilepsy', HUMAN MUTATION, 40 5-24 (2019)
DOI 10.1002/humu.23670
Citations Scopus - 38Web of Science - 28
2019 van der Sluijs PJ, Jansen S, Vergano SA, Adachi-Fukuda M, Alanay Y, AlKindy A, et al., 'The ARID1B spectrum in 143 patients: from nonsyndromic intellectual disability to Coffin-Siris syndrome', GENETICS IN MEDICINE, 21 1295-1307 (2019)
DOI 10.1038/s41436-018-0330-z
Citations Scopus - 70Web of Science - 54
2019 Li A, Geyer FC, Blecua P, Lee JY, Selenica P, Brown DN, et al., 'Homologous recombination DNA repair defects in
DOI 10.1038/s41523-019-0115-9
Citations Scopus - 36Web of Science - 27
Co-authors Rodney Scott, John Forbes
2019 Figlioli G, Bogliolo M, Catucci I, Caleca L, Viz Lasheras S, Pujol R, et al., 'The
DOI 10.1038/s41523-019-0127-5
Citations Scopus - 22Web of Science - 24
Co-authors John Forbes, Rodney Scott
2019 van der Sluijs PJ, Jansen S, Vergano SA, Adachi-Fukuda M, Alanay Y, AlKindy A, et al., 'The ARID1B spectrum in 143 patients: from nonsyndromic intellectual disability to Coffin-Siris syndrome (vol 21, pg 1295, 2019)', GENETICS IN MEDICINE, 21 2160-2161 (2019)
DOI 10.1038/s41436-018-0368-y
Citations Scopus - 5Web of Science - 3
2018 Kamien B, Ronan A, Poke G, Sinnerbrink I, Baynam G, Ward M, et al., 'A Clinical Review of Generalized Overgrowth Syndromes in the Era of Massively Parallel Sequencing', Molecular Syndromology, 9 70-82 (2018) [C1]
DOI 10.1159/000484532
Citations Scopus - 36Web of Science - 29
Co-authors Rodney Scott
2018 Jenkins ZA, Macharg A, Chang C-Y, van Kogelenberg M, Morgan T, Frentz S, et al., 'Differential regulation of two FLNA transcripts explains some of the phenotypic heterogeneity in the loss-of-function filaminopathies', HUMAN MUTATION, 39 103-113 (2018)
DOI 10.1002/humu.23355
Citations Scopus - 23Web of Science - 18
2018 Dagar V, Hutchison W, Muscat A, Krishnan A, Hoke D, Buckle A, et al., 'Genetic variation affecting DNA methylation and the human imprinting disorder, Beckwith-Wiedemann syndrome', CLINICAL EPIGENETICS, 10 (2018) [C1]
DOI 10.1186/s13148-018-0546-4
Citations Scopus - 9Web of Science - 9
2018 Ngoc MPN, Khawajkie Y, Mechtouf N, Rezaei M, Breguet M, Kurvinen E, et al., 'The genetics of recurrent hydatidiform moles: new insights and lessons from a comprehensive analysis of 113 patients', MODERN PATHOLOGY, 31 1116-1130 (2018)
DOI 10.1038/s41379-018-0031-9
Citations Scopus - 56Web of Science - 41
2018 Kumar R, Gardner A, Homan CC, Douglas E, Mefford H, Wieczorek D, et al., 'Severe neurocognitive and growth disorders due to variation in THOC2, an essential component of nuclear mRNA export machinery', HUMAN MUTATION, 39 1126-1138 (2018)
DOI 10.1002/humu.23557
Citations Scopus - 15Web of Science - 13
2017 Le Fevre A, Beygo J, Silveira C, Kamien B, Clayton-Smith J, Colley A, et al., 'Atypical Angelman syndrome due to a mosaic imprinting defect: Case reports and review of the literature', American Journal of Medical Genetics, Part A, 173 753-757 (2017) [C1]

Angelman syndrome (AS) is characterized by severe intellectual disability, limited, or absent speech and a generally happy demeanor. The four known etiological mechanisms; deletio... [more]

Angelman syndrome (AS) is characterized by severe intellectual disability, limited, or absent speech and a generally happy demeanor. The four known etiological mechanisms; deletions, uniparental disomy, imprinting defects, and UBE3A mutation all affect expression of the UBE3A gene at 15q11-q13. An atypical phenotype is seen in individuals who are mosaic for a chromosome 15q11-q13 imprinting defect on the maternal allele. These patients present with a milder phenotype, often with hyperphagia and obesity or non-specific intellectual disability. Unlike typical AS syndrome, they can have a vocabulary up to 100 words and speak in sentences. Ataxia and seizures may not be present, and the majority of individuals do not have microcephaly. Here we review the current literature and present three individuals with atypical AS caused by a mosaic imprinting defect to demonstrate why DNA methylation analysis at the SNRPN locus needs to be considered in a broader clinical context. © 2017 Wiley Periodicals, Inc.

DOI 10.1002/ajmg.a.38072
Citations Scopus - 19Web of Science - 17
2017 Dudding-Byth T, Baxter A, Holliday EG, Hackett A, O'Donnell S, White SM, et al., 'Computer face-matching technology using two-dimensional photographs accurately matches the facial gestalt of unrelated individuals with the same syndromic form of intellectual disability', BMC Biotechnology, 17 (2017) [C1]
DOI 10.1186/s12896-017-0410-1
Citations Scopus - 32Web of Science - 19
Co-authors John Attia, Carlos Riveros, Liz Holliday, A Hackett
2017 Palmer EE, Kumar R, Gordon CT, Shaw M, Hubert L, Carroll R, et al., 'A Recurrent De Novo Nonsense Variant in ZSWIM6 Results in Severe Intellectual Disability without Frontonasal or Limb Malformations', American Journal of Human Genetics, 101 995-1005 (2017) [C1]

A recurrent de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6 was previously reported to cause acromelic frontonasal dysostosis (AFND), an autosomal-domina... [more]

A recurrent de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6 was previously reported to cause acromelic frontonasal dysostosis (AFND), an autosomal-dominant severe frontonasal and limb malformation syndrome, associated with neurocognitive and motor delay, via a proposed gain-of-function effect. We present detailed phenotypic information on seven unrelated individuals with a recurrent de novo nonsense variant (c.2737C>T [p.Arg913Ter]) in the penultimate exon of ZSWIM6 who have severe-profound intellectual disability and additional central and peripheral nervous system symptoms but an absence of frontonasal or limb malformations. We show that the c.2737C>T variant does not trigger nonsense-mediated decay of the ZSWIM6 mRNA in affected individual-derived cells. This finding supports the existence of a truncated ZSWIM6 protein lacking the Sin3-like domain, which could have a dominant-negative effect. This study builds support for a key role for ZSWIM6 in neuronal development and function, in addition to its putative roles in limb and craniofacial development, and provides a striking example of different variants in the same gene leading to distinct phenotypes.

DOI 10.1016/j.ajhg.2017.10.009
Citations Scopus - 18Web of Science - 17
2017 Hwang YT, Dudding T, Mabel Aliaga S, Arpone M, Francis D, Li X, et al., 'Hwang Y.T. et al. Molecular Inconsistencies in a Fragile X Male with Early Onset Ataxia (vol 7, 68, 2016)', GENES, 8 (2017)
DOI 10.3390/genes8020047
2017 Zambonin JL, Bellomo A, Ben-Pazi H, Everman DB, Frazer LM, Geraghty MT, et al., 'Spinocerebellar ataxia type 29 due to mutations in ITPR1: A case series and review of this emerging congenital ataxia', Orphanet Journal of Rare Diseases, 12 1-8 (2017) [C1]
DOI 10.1186/s13023-017-0672-7
Citations Scopus - 38Web of Science - 27
2016 Kamien B, Dadd T, Buckman M, Ronan A, Dudding T, Meldrum C, et al., 'Somatic-Gonadal Mosaicism Causing Sotos Syndrome', AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 170 3360-3362 (2016)
DOI 10.1002/ajmg.a.37867
Citations Scopus - 1Web of Science - 1
Co-authors Rodney Scott
2016 McInerney-Leo AM, Harris JE, Gattas M, Peach EE, Sinnott S, Dudding-Byth T, et al., 'Fryns Syndrome Associated with Recessive Mutations in PIGN in two Separate Families', Human Mutation, 37 695-702 (2016) [C1]

Fryns syndrome is an autosomal recessive condition characterized by congenital diaphragmatic hernia (CDH), dysmorphic facial features, distal digital hypoplasia, and other associa... [more]

Fryns syndrome is an autosomal recessive condition characterized by congenital diaphragmatic hernia (CDH), dysmorphic facial features, distal digital hypoplasia, and other associated malformations, and is the most common syndromic form of CDH. No gene has been associated with this condition. Whole-exome sequence data from two siblings and three unrelated individuals with Fryns syndrome were filtered for rare, good quality, coding mutations fitting a recessive inheritance model. Compound heterozygous mutations in PIGN were identified in the siblings, with appropriate parental segregation: a novel STOP mutation (c.1966C>T: p.Glu656X) and a rare (minor allele frequency <0.001) donor splice site mutation (c.1674+1G>C) causing skipping of exon 18 and utilization of a cryptic acceptor site in exon 19. A further novel homozygous STOP mutation in PIGN (c.694A>T: p.Lys232X) was detected in one unrelated case. All three variants affected highly conserved bases. The two remaining cases were negative for PIGN mutations. Mutations in PIGN have been reported in cases with multiple congenital anomalies, including one case with syndromic CDH. Fryns syndrome can be caused by recessive mutations in PIGN. Whether PIGN affects other syndromic and non-syndromic forms of CDH warrants investigation.

DOI 10.1002/humu.22994
Citations Scopus - 37Web of Science - 34
2016 Petrovski S, Kury S, Myers CT, Anyane-Yeboa K, Cogne B, Bialer M, et al., 'Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures', AMERICAN JOURNAL OF HUMAN GENETICS, 98 1001-1010 (2016) [C1]
DOI 10.1016/j.ajhg.2016.03.011
Citations Scopus - 87Web of Science - 70
2016 Pelttari LM, Khan S, Vuorela M, Kiiski JI, Vilske S, Nevanlinna V, et al., 'RAD51B in familial breast cancer', PLoS ONE, 11 (2016) [C1]

Common variation on 14q24.1, close to RAD51B, has been associated with breast cancer: rs999737 and rs2588809 with the risk of female breast cancer and rs1314913 with the risk of m... [more]

Common variation on 14q24.1, close to RAD51B, has been associated with breast cancer: rs999737 and rs2588809 with the risk of female breast cancer and rs1314913 with the risk of male breast cancer. The aim of this study was to investigate the role of RAD51B variants in breast cancer predisposition, particularly in the context of familial breast cancer in Finland. We sequenced the coding region of RAD51B in 168 Finnish breast cancer patients from the Helsinki region for identification of possible recurrent founder mutations. In addition, we studied the known rs999737, rs2588809, and rs1314913 SNPs and RAD51B haplotypes in 44,791 breast cancer cases and 43,583 controls from 40 studies participating in the Breast Cancer Association Consortium (BCAC) that were genotyped on a custom chip (iCOGS). We identified one putatively pathogenic missense mutation c.541C>T among the Finnish cancer patients and subsequently genotyped the mutation in additional breast cancer cases (n = 5259) and population controls (n = 3586) from Finland and Belarus. No significant association with breast cancer risk was seen in the meta-analysis of the Finnish datasets or in the large BCAC dataset. The association with previously identified risk variants rs999737, rs2588809, and rs1314913 was replicated among all breast cancer cases and also among familial cases in the BCAC dataset. The most significant association was observed for the haplotype carrying the risk-alleles of all the three SNPs both among all cases (odds ratio (OR): 1.15, 95% confidence interval (CI): 1.11-1.19, P = 8.88 × 10-16) and among familial cases (OR: 1.24, 95% CI: 1.16-1.32, P = 6.19 × 10-11), compared to the haplotype with the respective protective alleles. Our results suggest that loss-of-function mutations in RAD51B are rare, but common variation at the RAD51B region is significantly associated with familial breast cancer risk.

DOI 10.1371/journal.pone.0153788
Citations Scopus - 19Web of Science - 19
Co-authors Rodney Scott
2016 Hwang YT, Dudding T, Mabel Aliaga S, Arpone M, Francis D, Li X, et al., 'Molecular Inconsistencies in a Fragile X Male with Early Onset Ataxia', GENES, 7 (2016)
DOI 10.3390/genes7090068
Citations Scopus - 7Web of Science - 8
2015 Oegema R, Cushion TD, Phelps IG, Chung SK, Dempsey JC, Collins S, et al., 'Recognizable cerebellar dysplasia associated with mutations in multiple tubulin genes', Human Molecular Genetics, 24 5313-5325 (2015) [C1]

Mutations in alpha- and beta-tubulins are increasingly recognized as a major cause of malformations of cortical development (MCD), typically lissencephaly, pachygyria and polymicr... [more]

Mutations in alpha- and beta-tubulins are increasingly recognized as a major cause of malformations of cortical development (MCD), typically lissencephaly, pachygyria and polymicrogyria; however, sequencing tubulin genes in large cohorts of MCD patients has detected tubulin mutations in only 1-13%. We identified patients with a highly characteristic cerebellar dysplasia but without lissencephaly, pachygyria and polymicrogyria typically associated with tubulin mutations. Remarkably, in seven of nine patients (78%), targeted sequencing revealed mutations in three different tubulin genes (TUBA1A, TUBB2B and TUBB3), occurring de novo or inherited from a mosaic parent. Careful re-review of the cortical phenotype on brain imaging revealed only an irregular pattern of gyri and sulci, for which we propose the term tubulinopathy-related dysgyria. Basal ganglia (100%) and brainstem dysplasia (80%) were common features. On the basis of in silico structural predictions, the mutations affect amino acids in diverse regions of the alpha-/beta-tubulin heterodimer, including the nucleotide binding pocket. Cell-based assays of tubulin dynamics reveal various effects of the mutations on incorporation into microtubules: TUBB3 p. Glu288Lys and p. Pro357Leu do not incorporate into microtubules at all, whereas TUBB2B p. Gly13Ala shows reduced incorporation and TUBA1A p. Arg214His incorporates fully, but at a slower rate than wild-type. The broad range of effects on microtubule incorporation is at odds with the highly stereotypical clinical phenotype, supporting differential roles for the three tubulin genes involved. Identifying this highly characteristic phenotype is important due to the low recurrence risk compared with the other (recessive) cerebellar dysplasias and the apparent lack of non-neurological medical issues.

DOI 10.1093/hmg/ddv250
Citations Scopus - 69Web of Science - 48
2015 Dudding-Byth T, 'A powerful team: The family physician advocating for patients with a rare disease', AUSTRALIAN FAMILY PHYSICIAN, 44 634-638 (2015) [C1]
Citations Scopus - 15Web of Science - 13
2015 Kamien B, Digilio MC, Novelli A, O'Donnell S, Bain N, Meldrum C, et al., 'Narrowing the critical region for overgrowth within 13q14.2-q14.3 microdeletions', European Journal of Medical Genetics, 58 629-633 (2015) [C3]

Large chromosomal deletions from 13q13.3 to 13q21.3 have previously been associated with overgrowth. We present two patients with deletions at 13q14.2q14.3 who have macrocephaly, ... [more]

Large chromosomal deletions from 13q13.3 to 13q21.3 have previously been associated with overgrowth. We present two patients with deletions at 13q14.2q14.3 who have macrocephaly, tall stature relative to their parents, cardiac phenotypes, and intellectual disability. This report narrows the critical region for tall stature, macrocephaly, and possibly cardiac disease. Crown

DOI 10.1016/j.ejmg.2015.10.006
Citations Scopus - 9Web of Science - 8
Co-authors Rodney Scott
2015 Corbett MA, Dudding-Byth T, Crock PA, Botta E, Christie LM, Nardo T, et al., 'A novel X-linked trichothiodystrophy associated with a nonsense mutation in RNF113A', Journal of Medical Genetics, 52 269-274 (2015) [C1]

Background: Trichothiodystrophy (TTD) is a group of rare autosomal recessive disorders that variably affect a wide range of organs derived from the neuroectoderm. The key diagnost... [more]

Background: Trichothiodystrophy (TTD) is a group of rare autosomal recessive disorders that variably affect a wide range of organs derived from the neuroectoderm. The key diagnostic feature is sparse, brittle, sulfur deficient hair that has a 'tiger-tail' banding pattern under polarising light microscopy. Patients and methods: We describe two male cousins affected by TTD associated with microcephaly, profound intellectual disability, sparse brittle hair, aged appearance, short stature, facial dysmorphism, seizures, an immunoglobulin deficiency, multiple endocrine abnormalities, cerebellar hypoplasia and partial absence of the corpus callosum, in the absence of cellular photosensitivity and ichthyosis. Obligate female carriers showed 100% skewed X-chromosome inactivation. Linkage analysis and Sanger sequencing of 737 X-chromosome exons and whole exome sequencing was used to find the responsible gene and mutation. Results: Linkage analysis localised the disease allele to a 7.75 Mb interval from Xq23-q25. We identified a nonsense mutation in the highly conserved RNF113A gene (c.901 C>T, p.Q301*). The mutation segregated with the disease in the family and was not observed in over 100 000 control X chromosomes. The mutation markedly reduced RNF113A protein expression in extracts from lymphoblastoid cell lines derived from the affected individuals. Conclusions: The association of RNF113A mutation with non-photosensitive TTD identifies a new locus for these disorders on the X chromosome. The extended phenotype within this family includes panhypopituitarism, cutis marmorata and congenital short oesophagus.

DOI 10.1136/jmedgenet-2014-102418
Citations Scopus - 39Web of Science - 32
Co-authors A Hackett
2015 van Kogelenberg M, Clark AR, Jenkins Z, Morgan T, Anandan A, Sawyer GM, et al., 'Diverse phenotypic consequences of mutations affecting the C-terminus of FLNA', JOURNAL OF MOLECULAR MEDICINE-JMM, 93 773-782 (2015) [C1]
DOI 10.1007/s00109-015-1261-7
Citations Scopus - 8Web of Science - 7
2013 Goel H, Dudding T, 'Carbimazole/Methimazole Embryopathy in Siblings: A Possible Genetic Susceptibility', BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 97 755-758 (2013)
DOI 10.1002/bdra.23200
Citations Scopus - 6Web of Science - 4
2012 Dudding TE, Attia JR, 'Maternal factor V Leiden and adverse pregnancy outcome: Deciding whether or not to test', Journal of Maternal-Fetal & Neonatal Medicine, 25 889-894 (2012) [C1]
Citations Scopus - 5Web of Science - 4
Co-authors John Attia
2012 Huang L, Chardon JW, Carter MT, Friend KL, Dudding TE, Schwartzentruber J, et al., 'Missense mutations in ITPR1 cause autosomal dominant congenital nonprogressive spinocerebellar ataxia', Orphanet Journal of Rare Diseases, 7 (2012) [C1]
DOI 10.1186/1750-1172-7-67
Citations Scopus - 115Web of Science - 98
Co-authors Peter Schofield
2011 Vilain RE, Dudding TE, Braye SG, Groombridge C, Meldrum C, Spigelman AD, et al., 'Can a familial gastrointestinal tumour syndrome be allelic with Waardenburg syndrome?', Clinical Genetics, 79 554-560 (2011) [C3]
DOI 10.1111/j.1399-0004.2010.01489.x
Citations Scopus - 11Web of Science - 11
Co-authors Stephen Ackland, Rodney Scott, Leonie Ashman
2010 Zilliacus E, Meiser B, Lobb E, Dudding TE, Barlow-Stewart K, Tucker K, 'The virtual consultation: Practitioners' experiences of genetic counseling by videoconferencing in Australia', Telemedicine Journal and E-Health, 16 350-357 (2010) [C1]
DOI 10.1089/tmj.2009.0108
Citations Scopus - 43Web of Science - 35
2010 Dudding TE, Lawrence O, Winship I, Froyen G, Vandewalle J, Scott R, Shelling AN, 'Array comparative genomic hybridization for the detection of submicroscopic copy number variations of the X chromosome in women with premature ovarian failure', Human Reproduction, 25 3159-3160 (2010) [C3]
Citations Scopus - 19Web of Science - 14
Co-authors Rodney Scott
2010 Truong HT, Dudding TE, Blanchard CL, Elsea SH, 'Frameshift mutation hotspot identified in Smith-Magenis syndrome: case report and review of literature', BMC Medical Genetics, 11 1-5 (2010) [C3]
Citations Scopus - 30Web of Science - 26
2008 Winship IM, Dudding TE, 'Lessons from the skin: Cutaneous features of familial cancer', Lancet Oncology, 9 462-472 (2008) [C1]
DOI 10.1016/S1470-2045(08)70126-8
Citations Scopus - 40Web of Science - 32
2008 Dudding TE, Heron J, Thakkinstian A, Nurk E, Golding J, Pembrey M, et al., 'Factor V Leiden is associated with pre-eclampsia but not with fetal growth restriction: A genetic association study and meta-analysis', Journal of Thrombosis and Haemostasis, 6 1868-1875 (2008) [C1]
DOI 10.111/j.1538-7836.2008.03134.x
Citations Scopus - 47Web of Science - 43
Co-authors Rodney Scott, John Attia
2008 Wakefield CE, Meiser B, Homewood J, Taylor A, Gleeson M, Williams R, et al., 'A randomized trial of a breast/ovarian cancer genetic testing decision aid used as a communication aid during genetic counseling', Psycho-Oncology, 17 844-854 (2008)

Objectives: To evaluate the impact of a decision aid for women considering genetic testing for breast/ovarian cancer risk given during genetic counseling. Methods: One hundred and... [more]

Objectives: To evaluate the impact of a decision aid for women considering genetic testing for breast/ovarian cancer risk given during genetic counseling. Methods: One hundred and forty-eight women were randomized to receive the decision aid or a control pamphlet at the beginning of their first consultation with a genetic counselor. When the patient received the decision aid, it was used to complement consultation discussions about genetic testing. One hundred and ten (74.3%) women completed the first questionnaire designed to elicit information about women's levels of decisional conflict and knowledge about genetic testing. Of these, 105 (70.9%) completed a second questionnaire to assess longer-term outcomes, 6 months postconsultation. Results: Results showed that women who received the decision aid felt more informed about genetic testing (¿2(1) = 8.69; P = 0.003), had clearer values (¿2(1) = 6.90; P = 0.009) and had higher knowledge levels (¿2(2) = 6.49; P = 0.039) than women who received the control pamphlet. Conclusions: The developed decision aid improved patient outcomes better than a control pamphlet when implemented during genetic counseling and given to the patient to take home. Copyright © 2008 John Wiley & Sons, Ltd.

DOI 10.1002/pon.1353
Citations Scopus - 44
2008 Ronan A, Buiting K, Dudding TE, 'Atypical Angelman syndrome with macrocephaly due to a familial imprinting center deletion', American Journal of Medical Genetics Part A, 146A 78-82 (2008) [C1]
DOI 10.1002/ajmg.a.31952
Citations Scopus - 6Web of Science - 7
2008 Wakefield CE, Meiser B, Homewood J, Peate M, Taylor A, Lobb E, et al., 'A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk', Breast Cancer Research and Treatment, 107 289-301 (2008)

Purpose: To measure the effectiveness of a tailored decision aid (DA) designed to help women make informed decisions about genetic testing for breast/ovarian cancer risk. Methods:... [more]

Purpose: To measure the effectiveness of a tailored decision aid (DA) designed to help women make informed decisions about genetic testing for breast/ovarian cancer risk. Methods: A total of 145 women were randomized to receive the DA or a control pamphlet at the end of their first genetic counseling consultation. Of these, 120 (82.8%) completed two questionnaires, 1 week and 6 months post-consultation. Results: While the DA had no effect on informed choice, post-decisional regret or actual genetic testing decision, the trial showed that women who received the DA had higher knowledge levels and felt more informed about genetic testing than women who received the control pamphlet (¿ 2(2) = 6.82; P = 0.033; ¿ 2(1) = 4.86; P = 0.028 respectively). The DA also helped women who did not have blood drawn at their first consultation to clarify their values with regards to genetic testing (¿ 2(1) = 5.27; P = 0.022). Women who received the DA were less likely to share the information with other family members than women in the control condition (¿ 2(1) = 8.78; P = 0.003). Conclusions: Decision aids are an effective decision-support strategy for women considering genetic testing for breast/ovarian cancer risk, and are most effective before the patient has made a decision, which is generally at the point of having blood drawn. © 2007 Springer Science+Business Media, LLC.

DOI 10.1007/s10549-007-9539-2
Citations Scopus - 64
2008 Wakefield CE, Spigelman A, 'Randomized trial of a decision aid for individuals considering genetic testing for hereditary nonpolyposis colorectal cancer risk', Cancer, 113 956-965 (2008) [C1]
Citations Scopus - 48Web of Science - 43
2007 Easton DF, Search Collaborators Including, Forbes JF, 'Genome-wide association study identifies novel breast cancer susceptibility loci', Nature, 447 1087-1093 (2007) [C1]
DOI 10.1038/nature05887
Citations Scopus - 1941Web of Science - 1777
Co-authors John Forbes, Rodney Scott
2006 Yoland A, John R, Mary-Anne Y, Judy K, Katherine T, Tarli B, et al., 'Risk-reducing surgery in women with familial susceptibility for breast and /or ovarian cancer', European Journal of Cancer, 42 621-628 (2006) [C1]
DOI 10.1016/j.ejca.2005.11.020
Citations Scopus - 38Web of Science - 35
2006 Antill YC, Reynolds J, Young MA, Kirk JA, Tucker KM, Bogtstra TL, et al., 'Screening behavior in women at increased familial risk for breast cancer', Familial Cancer, 5 359-368 (2006) [C1]
DOI 10.1007/s10689-006-0006-8
Citations Scopus - 36Web of Science - 33
2006 Tiller K, Meiser B, Gaff C, Kirk J, Dudding TE, Phillips KA, et al., 'A randomized controlled trial of a decision aid for women at increased risk of ovarian cancer', Medical Decision Making, 26 360-372 (2006) [C1]
DOI 10.1177/0272989X06290486
Citations Scopus - 30Web of Science - 26
2006 Lobb EA, Butow PN, Moore A, Barratt A, Tucker K, Gaff C, et al., 'Development of a communication aid to facilitate risk communication in consultations with unaffected women from high risk breast cancer families: a pilot study', Journal of Genetic Counselling, 15 393-405 (2006) [C1]
DOI 10.1007/s10897-006-9023-x
Citations Scopus - 25
2005 Lindqvist PG, Merlo J, Dudding T, Attia J, 'Rebuttal: Meta-analysis of the relationship of factor V Leiden and intrauterine growth restriction-based on solid evidence? (multiple letters) [6]', Thrombosis and Haemostasis, 94 230-232 (2005)
DOI 10.1055/s-0037-1614316
Citations Scopus - 1
Co-authors John Attia
2005 Dudding T, Attia JR, 'Response to Rebuttal: Meta-analysis of the relationship of factor V Leiden and intrauterine growth restriction-based on solid evidence? (letter)', Thrombosis and Haemostasis, 94 230-232 (2005) [C3]
2005 Lubinski J, Lynch HT, Schmutzler R, Brood-Van Zanten MMA, Van Der Mooren MJ, Verheijen RHM, et al., 'Hormone replacement therapy appears to be safe after prophylactic adnexectomy in premenopausal BRCA1/BRCA2 mutation carriers', Hereditary Cancer in Clinical Practice, 3 87-91 (2005)
2005 Tiller K, Meiser B, Gould L, Tucker K, Dudding TE, Franklin J, et al., 'Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer', Psycho-Oncology, 14 249-261 (2005) [C1]
DOI 10.1002/pon.840
Citations Scopus - 24Web of Science - 22
2004 Dudding TE, Friend K, Schofield PW, Lee SJ, Wilkinson IA, Richards R, 'Autosomal dominant congenital non-progressive ataxia overlaps with the SCA15 locus', Neurology, 63 2288-2292 (2004) [C1]
DOI 10.1212/01.WNL.0000147299.80872.D1
Citations Scopus - 75Web of Science - 56
Co-authors Peter Schofield
2004 Attia J, Dudding T, Infante-Rivard C, 'The association between adverse pregnancy outcomes and maternal factor V Leiden genotype. a meta-analysis. (vol 91, pg 700, 2004)', THROMBOSIS AND HAEMOSTASIS, 92 434-434 (2004)
DOI 10.1055/s-0037-1613736
Citations Web of Science - 1
2004 Attia JR, Dudding TE, Infante-Rivard C, 'Addendum to: The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: A meta-analysis', Thrombosis and Haemostasis, 92 434 (2004) [C3]
Citations Scopus - 2
Co-authors John Attia
2004 Dudding TE, Attia JR, 'The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis', Journal of Thrombosis and Haemostasis, 91 700-711 (2004) [C2]
Citations Scopus - 116Web of Science - 90
Co-authors John Attia
2003 Groombridge C, Ingrey AJ, Gleeson M, Spigelman AD, Dudding TE, 'Factors influencing the dissemination of genetic information in families with an inherited predisposition to colorectal cancer', Familial Cancer, 2 69 (2003) [C3]
2001 Meiser B, Butow P, Barratt A, Gattas M, Gaff C, Haan E, et al., 'Risk perceptions and knowledge of breast cancer genetics in women at increased risk of developing hereditary breast cancer', Psychology & Health, 16 297-311 (2001) [C1]
DOI 10.1080/08870440108405508
Citations Scopus - 36
2000 Dudding TE, Wilcken B, Burgess BT, Turner G, 'Neonatal screening for cystic fibrosis', The Lancet, 356 1930 (2000) [C3]
Citations Scopus - 10
2000 Dudding TE, Wilcken B, Burgess BT, Hambly J, Turner G, 'Reproductive decisions after neonatal screening identifies cystic fibrosis', Archives of Disease in Childhood (Fetal and Neonatal Edition), 82 F124-F127 (2000) [C1]
Citations Scopus - 50
1998 Dudding TE, Rogers M, Roddick LG, Relic J, Edwards MJ, 'Nevoid hypertrichosis with multiple patches of hair that underwent almost complete spontaneous resolution', AMERICAN JOURNAL OF MEDICAL GENETICS, 79 195-196 (1998)
DOI 10.1002/(SICI)1096-8628(19980923)79:3&lt;195::AID-AJMG8&gt;3.0.CO;2-M
Citations Scopus - 11Web of Science - 6
1998 Evans DGR, Hill J, Dudding T, Burn J, Maher ER, 'Molecular genetic tests in surgical management of familial adenomatous polyposis - reply', LANCET, 351 1131-1132 (1998)
DOI 10.1016/S0140-6736(05)79414-9
Citations Scopus - 7
1997 Evans DGR, Hill J, Dudding TE, Burn J, Maher ER, 'Molecular genetic tests in surgical management of familial adenomatous polyposis', The Lancet, 350 1777 (1997) [C3]
DOI 10.1016/s0140-6736(05)63606-9
Citations Scopus - 11Web of Science - 12
Show 76 more journal articles

Conference (5 outputs)

Year Citation Altmetrics Link
2005 McKenzie F, Dudding TE, Edwards MJ, Giles WB, Hackett AK, Somerset D, Woodford P, 'Review of late fetal loss in the Hunter and proposed strategies for investigation', Human Genetics Society of Australasia, Newcastle (2005) [E3]
Co-authors A Hackett
2004 McKenzie F, Dudding TE, Fagan KA, Edwards MJ, 'Subtelomere FISH in the Hunter', Conference Abstract, Fremantle, Western Australia (2004) [E3]
2004 Dudding TE, Christie L, Crawford J, Gecz J, Turner G, 'The use of skewed maternal X inactivation in prenatal counselling', Conference Abstract, Fremantle, Western Australia (2004) [E3]
2004 Antill Y, Dudding TE, Hall T, Kirk J, Reynolds J, Tucker K, et al., 'Breast and ovarian cancer screening practices and prophylactic surgery in at risk women: an Australian multicenter study', Poster Presentation, Toronto, Ontario, Canada (2004) [E3]
2003 Spigelman AD, Gani JS, Burgess BT, Groombridge C, Dudding TE, Ingrey AJ, et al., 'Advanced Duodenal Polyposis: Literature review and experience with pancreas-sparing duodenectomy inpatients with familial adenomatous polyposis (FAP)', Familial Cancer, Cleveland, Ohio (2003) [E4]
Co-authors Jonathan Gani, Maree Gleeson, Rodney Scott
Show 2 more conferences
Edit

Grants and Funding

Summary

Number of grants 11
Total funding $8,488,980

Click on a grant title below to expand the full details for that specific grant.


20232 grants / $5,004,310

Using polygenic scores to guide the treatment and prophylaxis of hypertension$2,687,424

Funding body: Department of Health and Aged Care

Funding body Department of Health and Aged Care
Project Team Professor Murray Cairns, Professor Aaron Sverdlov, Professor Andrew Boyle, Professor Doan Ngo, Professor John Attia, Professor Clare Collins, Professor Christopher Reid, Prof Christopher Reid , Doctor William Reay, Dr Tracy Dudding-Byth, Dr Anastasia Mihaildou , Dr Anastasia Mihailidou, Doctor Tracy Dudding, Prof Andrew Boyle
Scheme MRFF - GHFM - Genomics Health Futures Mission
Role Investigator
Funding Start 2023
Funding Finish 2027
GNo G2300029
Type Of Funding C1300 - Aust Competitive - Medical Research Future Fund
Category 1300
UON Y

Facematch: Harnessing frontier technologies in facial recognition to transform genetic diagnosis of children with moderate to severe intellectual disability$2,316,886

Funding body: Department of Health and Aged Care

Funding body Department of Health and Aged Care
Project Team Doctor Tracy Dudding, Doctor Tracy Dudding, Professor John Attia, Professor Melissa Wake, Doctor Carlos Riveros, Associate Professor Raymond Chiong, Dr Carlos Riveros, Professor Sandra Cooper, Prof Sandra Cooper , Prof Elizabeth Elliot , Professor Elizabeth Elliot, Dr Anthea Bill , Dr Himanshu Goel , Associate Professor Helen Leonard, AProf Helen Leonard , Dr Michael Field, Dr Benjamin Kamien , Doctor Himanshu Goel, Ms Jackie Boyle, Brian Lovell
Scheme MRFF - GHFM - Genomics Health Futures Mission
Role Lead
Funding Start 2023
Funding Finish 2027
GNo G2300080
Type Of Funding C1300 - Aust Competitive - Medical Research Future Fund
Category 1300
UON Y

20221 grants / $50,000

FaceMatch: Searching for a diagnosis$50,000

Funding body: Woodend Foundation

Funding body Woodend Foundation
Project Team Doctor Tracy Dudding, Professor John Attia, Dr Carlos Riveros
Scheme Research Grant
Role Lead
Funding Start 2022
Funding Finish 2022
GNo G2101243
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON Y

20211 grants / $1,707,163

The Neurofibromatosis type 1 (NF1) Cutaneous Neurofibroma Consortium: Identifying Genetic modifiers of disease burden to inform treatment pathways$1,707,163

Funding body: Department of Health and Aged Care

Funding body Department of Health and Aged Care
Project Team Doctor Tracy Dudding, Professor Murray Cairns, Professor John Attia, Professor D Gareth Evans, Gareth Evans, Professor Rodney Scott, Professor Brian Lovell, Brian Lovell, Adrian Lim, Dr Adrian Lim, Katharine Drummond, Eryn Dow, Nicola Poplawski, Benjamin Kamien, Yemima Berman, Natalie McCloughan
Scheme MRFF - EPCDRI - Neurofibromatosis
Role Lead
Funding Start 2021
Funding Finish 2024
GNo G2100411
Type Of Funding C1300 - Aust Competitive - Medical Research Future Fund
Category 1300
UON Y

20191 grants / $115,507

Transforming the Genomic Diagnosis and Management of Severe Neurocognitive Disorders$115,507

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Tracy Dudding, Tony Roscioli, Professor Jozef Gecz, Dr Michael Field, Professor Deborah Schofield, Dr Michael Buckley, Professor Kathryn North, Associate Professor Marcel Dinger, Professor John Christodoulou, Professor David Amor, Associate Professor Gareth Baynam
Scheme Centres of Research Excellence (CRE) - Centres of Population Health Research Excellence
Role Lead
Funding Start 2019
Funding Finish 2022
GNo G1801092
Type Of Funding C1100 - Aust Competitive - NHMRC
Category 1100
UON Y

20081 grants / $300,000

Platform technology capacity building grant: Consortium for the Inherited Renal Malignancies (CONFIRM)$300,000

Funding body: Victorian Cancer Agency

Funding body Victorian Cancer Agency
Project Team

Jenkins M,Southery M, Carrol, R, Bogwitz M, Goldar D, Dudding T, Tucker K.

Scheme Seed funding
Role Investigator
Funding Start 2008
Funding Finish 2009
GNo
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON N

20062 grants / $1,017,000

Strategic research partnership grant$1,000,000

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team

Meiser B, Lobb E, Tucker K, Andrews L, Kirk J, Friedlander M, Mireskandari S, Kasparian N, Wakefield C, Dudding T.

Scheme Project Grant
Role Investigator
Funding Start 2006
Funding Finish 2010
GNo
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON N

The use of array based comparative genomic hybridization for the detection of sub-microscopic x-chromosomal abnormalities in women with premature ovarian failure$17,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Tracy Dudding, Conjoint Professor Gillian Turner
Scheme Project Grant
Role Lead
Funding Start 2006
Funding Finish 2006
GNo G0186095
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20022 grants / $280,000

A Nested Case Control Study evaluating the association between the factor V Leiden genotype and adverse pregnancy outcome$165,000

Funding body: National Health and Medical Research Council

Funding body National Health and Medical Research Council
Project Team

Scott, R; Dudding-Byth, T.

Scheme Project Grant
Role Investigator
Funding Start 2002
Funding Finish 2004
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

A randomised trial of a decision aid for women at risk of ovarian cancer$115,000

Funding body: National Health and Medical Research Council

Funding body National Health and Medical Research Council
Project Team

Friedlander M, Tiller K, Kirk J, Gaff C. Associate investigators: Dudding-Byth T, Meiser B, Tucker K, Reeson L, Robertson G, Hammond.

Scheme Project Grant
Role Investigator
Funding Start 2002
Funding Finish 2002
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

20011 grants / $15,000

Congenital thrombophilia and adverse pregnancy outcome$15,000

Funding body: Charitable Trust

Funding body Charitable Trust
Scheme Seed funding
Role Lead
Funding Start 2001
Funding Finish 2001
GNo
Type Of Funding Not Known
Category UNKN
UON N
Edit

Research Supervision

Number of supervisions

Completed3
Current0

Past Supervision

Year Level of Study Research Title Program Supervisor Type
2021 PhD The Genetics of Overgrowth Syndromes PhD (Medical Genetics), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
2021 Masters An Exploration of the Diagnostic Journey of Children with Neuronal Ceroid Lipofuscinosis (NCL) M Philosophy (Nursing), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
2017 PhD From General Developmental Disability to 22Q11.2 Deletion Syndrome: Understanding Parental Experiences PhD (Psychology - Science), College of Engineering, Science and Environment, The University of Newcastle Co-Supervisor
Edit

Research Collaborations

The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.

Country Count of Publications
Australia 78
United Kingdom 33
United States 27
Canada 21
France 17
More...
Edit

News

MRFF grants

News • 23 Nov 2023

$9.3m awarded to Newcastle health research projects aiming to improve lives

Using facial recognition to transform genetic diagnosis of children with intellectual disability and a community-led breastfeeding support program for Indigenous families are among five Hunter research projects awarded more than $9.3m in Australian government health and medical funding.

News • 8 Jul 2021

Medical Research Future Fund success for key health initiatives

Three University of Newcastle-led research teams have secured more than $3.5 million through the Australian Government's Medical Research Future Fund, bolstering the University’s commitment to better, healthier living within our regions and beyond.

Tracy Dudding-Byth and Ainsely Hayes with her daughter Charleigh

News • 4 Apr 2018

Finding a FaceMatch could unlock genetic puzzles

Unravelling the mysteries behind undiagnosed intellectual disabilities in children might be a step closer thanks to a first-of-its-kind web platform launched today at the Hunter Medical Research Institute (HMRI).

Dr Tracy Dudding

Position

Conjoint Professor
School of Medicine and Public Health
College of Health, Medicine and Wellbeing

Focus area

Medical Genetics

Contact Details

Email t.dudding@newcastle.edu.au
Phone (02) 4985 3100
Fax (02) 4925 3133

Office

Building Newcastle Western Suburbs Hospital
Location Other

,
Edit